カテゴリ： GlobalData, アメリカ, 企業調査

Immunomedics Inc (IMMU)：製薬・医療：M&Aディール及び事業提携情報

◆英語タイトル：Immunomedics Inc (IMMU) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA904C12395
◆発行会社（調査会社）：GlobalData
◆発行日：2018年12月
◆ページ数：82
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：アメリカ
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
Immunomedics Inc (Immunomedics) is a clinical-stage bio-pharmaceutical company that researches, develops, manufactures and commercializes monoclonal antibody-based drugs for the treatment of cancer and autoimmune disorders. The company develops its candidates based on its proprietary technologies namely, ADC Linker technology and Dock-And-Lock platform. Its lead product candidate is Sacituzumab govitecan (IMMU-132) in Phase II development stage received breakthrough therapy designation from the US FDA for the treatment of patients with metastatic triple-negative breast cancer and metastatic solid cancers. Immunomedics’ other lead product candidates include Labetuzumab Govitecan (IMMU-130) and Epratuzumab. It also has other product candidates that target solid tumors, hematologic malignancies and other diseases, in various stages of clinical and pre-clinical development. The company also manufactures and commercializes diagnostic imaging product named, LeukoScan. Immunomedics is headquartered in Morris Plains, New Jersey, the US.

Immunomedics Inc (IMMU) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Immunomedics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Immunomedics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Immunomedics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Immunomedics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Immunomedics Inc, Medical Devices Deals, 2012 to YTD 2018 10
Immunomedics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Immunomedics Inc, Pharmaceuticals & Healthcare, Deal Details 12
Partnerships 12
Immunomedics Enters into Research Agreement with Yale Cancer Center 12
Immunomedics Enters into Research Agreement with Memorial Sloan Kettering Cancer Center 13
Immunomedics Enters into Research Agreement with Fred Hutchinson Cancer Research Center 14
Immunomedics Expands Clinical Collaboration with AstraZeneca 15
Clovis Oncology Enters into Agreement with Immunomedics 16
Immunomedics Enters into Agreement with University of Wisconsin Carbone Cancer Center 17
Immunomedics Enters Into Co-Devlopment Agreement With Algeta For Epratuzumab 18
Equity Offering 19
Immunomedics Raises USD276 Million in Public Offering of Shares 19
Immunomedics to Raise USD75 Million in Private Placement of Shares 21
Immunomedics Plans to Raise Funds through Public Offering of Shares 23
Immunomedics Raises USD125 Million in Private Placement of Series A-1 Preferred Stock 24
Immunomedics Raises USD30 Million in Public Offering of Shares and Warrants 25
Immunomedics Completes Public Offering Of Shares For US$30.2 Million 27
Immunomedics Completes Public Offering Of Common Stock For US$16 Million 29
Debt Offering 30
Immunomedics Raises USD85 Million in Private Placement of 4.75% Notes Due 2020 30
Asset Transactions 32
Royalty Pharma to Acquire Royalty Rights of Sacituzumab Govitecan from Immunomedics for USD175 Million 32
Acquisition 33
Seattle Genetics Acquires 2.8% Stake in Immunomedics 33
Immunomedics Inc – Key Competitors 35
Immunomedics Inc – Key Employees 36
Immunomedics Inc – Locations And Subsidiaries 37
Head Office 37
Other Locations & Subsidiaries 37
Recent Developments 38
Financial Announcements 38
Nov 07, 2018: Immunomedics announces first quarter fiscal 2019 results and provides corporate update 38
Aug 23, 2018: Immunomedics announces fourth quarter and fiscal year 2018 results and provides corporate update 40
May 09, 2018: Immunomedics Announces Third Quarter Fiscal 2018 Results and Provides Corporate Update 42
Feb 08, 2018: Immunomedics Announces Second Quarter Fiscal 2018 Results and Provides Corporate Update 44
Nov 09, 2017: Immunomedics Announces First Quarter Fiscal 2018 Results and Provides Corporate Update 46
Aug 16, 2017: Immunomedics Announces Fiscal 2017 Results and Strategic Developments; Reiterates Guidance on BLA Submission Timeline 48
May 10, 2017: Immunomedics Announces Third Quarter Fiscal 2017 Results And Clinical Program Developments 50
Feb 09, 2017: Immunomedics Announces Second Quarter Fiscal 2017 Results and Clinical Program Developments 52
Corporate Communications 54
Apr 09, 2018: Immunomedics Appoints Dr. Robert Iannone Head of Research & Development and Chief Medical Officer 54
Jan 09, 2017: Immunomedics Announces Reconstituted Board of Directors and Leadership Succession Plan 55
Legal and Regulatory 56
Feb 21, 2017: Immunomedics Files Federal Lawsuit Against venBio for Continuing Material Violations of the Federal Securities Laws 56
Government and Public Interest 57
May 05, 2017: Immunomedics Delivers Business Updates, Announces Private Placement Offering and Outlines Strategic Steps to Drive Stockholder Value 57
Product News 60
11/09/2017: Immunomedics Appoints Michael Pehl President and Chief Executive Officer to Lead Next Phase of Transformative Growth 60
02/23/2017: Immunomedics Announces Company’s Immune Checkpoint Inhibitor Enhances Anti-Tumor Potency of T-Cell-Redirecting Bispecific Antibodies 62
02/17/2017: Immunomedics Presents Updated Results With Sacituzumab Govitecan (IMMU-132) in Heavily-Pretreated Patients With Metastatic Urothelial Cancer 63
01/26/2017: venBio Releases Presentation Detailing Urgent Case for Change at Immunomedics 64
01/18/2017: Immunomedics Announces New Data for IMMU-132 at Investor R&D Day 65
Product Approvals 68
Aug 16, 2017: Immunomedics provides update on IMMU-132 68
Clinical Trials 69
Dec 06, 2017: Immunomedics Announces Updated Results With Sacituzumab Govitecan (IMMU-132) In Patients With Relapsed Or Refractory Metastatic Triple-Negative Breast Cancer (mTNBC) 69
Nov 13, 2017: Immunomedics Announces Presentations and Investor Event at the 2017 San Antonio Breast Cancer Symposium 70
Sep 11, 2017: Immunomedics Presents Interim Phase 2 Results With Sacituzumab Govitecan (IMMU-132) in Patients With Pretreated Metastatic Urothelial Cancer 71
Aug 21, 2017: Immunomedics Announces Publication of Phase 2 Results With Labetuzumab Govitecan That Demonstrate Promising Efficacy as a Single Agent in Patients With Metastatic Colorectal Cancer 72
Jul 10, 2017: Published Results from Clinical Trials Demonstrate Therapeutic Potential for Immunomedics’ Sacituzumab Govitecan (IMMU-132) in the Treatment of Metastatic Solid Cancers 73
Apr 05, 2017: Immunomedics Reports Sacituzumab Govitecan (IMMU-132) is Active in Patients with Metastatic Small-Cell Lung Cancer who are Sensitive or Resistant to First-Line Chemotherapy 75
Apr 04, 2017: Immunomedics Presents Preclinical Study That Demonstrates Increased SN-38 Delivery With Labetuzumab Govitecan (IMMU-130) Compared With Irinotecan 76
Apr 04, 2017: Immunomedics Reports Sacituzumab Govitecan (Immu-132) Delivers High Levels of sn-38 That Overcome Chemoresistant Tumors With Moderate to Strong Trop-2 Expression 77
Mar 15, 2017: Immunomedics Announces Publication of Results in Journal of Clinical Oncology, Demonstrating Treatment With Sacituzumab Govitecan (IMMU-132) Produces Early and Durable Responses in Patients With Metastatic Triple-Negative Breast Cancer 78
Jan 09, 2017: Immunomedics Announces Antitumor Effect of Sacituzumab Govitecan (IMMU-132) in Triple-Negative Breast Cancer Can be Enhanced With DNA-Repair Inhibitors 80
Appendix 82
Methodology 82
About GlobalData 82
Contact Us 82
Disclaimer 82

List of Tables
Immunomedics Inc, Pharmaceuticals & Healthcare, Key Facts, 2018 2
Immunomedics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Immunomedics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Immunomedics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Immunomedics Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Immunomedics Inc, Medical Devices Deals, 2012 to YTD 2018 10
Immunomedics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Immunomedics Enters into Research Agreement with Yale Cancer Center 12
Immunomedics Enters into Research Agreement with Memorial Sloan Kettering Cancer Center 13
Immunomedics Enters into Research Agreement with Fred Hutchinson Cancer Research Center 14
Immunomedics Expands Clinical Collaboration with AstraZeneca 15
Clovis Oncology Enters into Agreement with Immunomedics 16
Immunomedics Enters into Agreement with University of Wisconsin Carbone Cancer Center 17
Immunomedics Enters Into Co-Devlopment Agreement With Algeta For Epratuzumab 18
Immunomedics Raises USD276 Million in Public Offering of Shares 19
Immunomedics to Raise USD75 Million in Private Placement of Shares 21
Immunomedics Plans to Raise Funds through Public Offering of Shares 23
Immunomedics Raises USD125 Million in Private Placement of Series A-1 Preferred Stock 24
Immunomedics Raises USD30 Million in Public Offering of Shares and Warrants 25
Immunomedics Completes Public Offering Of Shares For US$30.2 Million 27
Immunomedics Completes Public Offering Of Common Stock For US$16 Million 29
Immunomedics Raises USD85 Million in Private Placement of 4.75% Notes Due 2020 30
Royalty Pharma to Acquire Royalty Rights of Sacituzumab Govitecan from Immunomedics for USD175 Million 32
Seattle Genetics Acquires 2.8% Stake in Immunomedics 33
Immunomedics Inc, Key Competitors 35
Immunomedics Inc, Key Employees 36
Immunomedics Inc, Subsidiaries 37

List of Figures
Immunomedics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Immunomedics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Immunomedics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Immunomedics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Immunomedics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Immunomedics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Immunomedics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Immunomedics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Immunomedics Inc, Medical Devices Deals, 2012 to YTD 2018 10

★海外企業調査レポート[Immunomedics Inc (IMMU)：製薬・医療：M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • Active Motif Inc-製薬・医療分野：企業M&A・提携分析
    Summary Active Motif Inc (Active Motif) is a healthcare company that develops and delivers biological research tools. The company’s products comprise antibodies, extracts, fluorescent dyes, kits, reporter assays, molecules and recombinant proteins. It offers products for transcriptional regulation, …
  • The Andersons Inc (ANDE)：企業の財務・戦略的SWOT分析
    The Andersons Inc (ANDE) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Shriram Transport Finance Company Ltd.：企業のM&A・事業提携・投資動向
    Shriram Transport Finance Company Ltd. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Shriram Transport Finance Company Ltd. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed repo …
  • Eurofins Scientific SE：企業の戦略・SWOT・財務情報
    Eurofins Scientific SE - Strategy, SWOT and Corporate Finance Report Summary Eurofins Scientific SE - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Intas Pharmaceuticals Ltd：企業の戦略的SWOT分析
    Intas Pharmaceuticals Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …
  • Respira Therapeutics Inc：医療機器：M&Aディール及び事業提携情報
    Summary Respira Therapeutics Inc (Respira) is a pharmaceutical development company that develops dry powder inhaler technologies. The company develops Inhaler technologies to enable targeted lung delivery of drugs to treat pulmonary diseases. It develops products used for the treatment of pulmonary …
  • CITIC Securities Company Limited：戦略・SWOT・企業財務分析
    CITIC Securities Company Limited - Strategy, SWOT and Corporate Finance Report Summary CITIC Securities Company Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, produ …
  • Asarina Pharma AB：製薬・医療：M&Aディール及び事業提携情報
    Summary Asarina Pharma AB (Asarina Pharma), formerly Umecrine Mood AB, a subsidiary of Umecrine AB, is a sepranolone product developer. The company offers discovery, development and commercialization of novel treatments for women suffering from premenstrual dysphoric disorder and other menstrual cyc …
  • CivaTech Oncology Inc-医療機器分野：企業M&A・提携分析
    Summary CivaTech Oncology Inc (CivaTech) is a medical device company that provides radiation therapy solutions. The company develops polymer based low dose rate (LDR) brachytherapy devices for the treatment of cancer. Its product portfolio includes CivaString, a radiation therapy device to treat sol …
  • Infinity Pharmaceuticals Inc (INFI)：企業の財務・戦略的SWOT分析
    Infinity Pharmaceuticals Inc (INFI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Astellas Pharma Inc.：企業の戦略・SWOT・財務情報
    Astellas Pharma Inc. - Strategy, SWOT and Corporate Finance Report Summary Astellas Pharma Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • XenoPort Inc-製薬・医療分野：企業M&A・提携分析
    Summary XenoPort Inc (XenoPort) is a bio-pharmaceutical company which develops and commercializes internally discovered product candidates for the treatment of neurological disorders. It develops Transported Prodrugs through the modification of chemical structure of existing drugs in the market. The …
  • National Grid Plc (NG)：電力：M&Aディール及び事業提携情報
    Summary National Grid Plc (National Grid) is an energy utility. It transmits and distributes electricity and gas. The company owns and operates electricity and gas transmission and distribution networks; and is also the system operator for the Scottish networks. National Grid provides installation a …
  • Catalent Inc：企業の戦略・SWOT・財務情報
    Catalent Inc - Strategy, SWOT and Corporate Finance Report Summary Catalent Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • Oasis Diagnostics Corp：企業の製品パイプライン分析2018
    Summary Oasis Diagnostics Corp (Oasis Diagnostics) is a medical device company that develops and commercializes tools for non-invasive diagnosis and detection of diseases. The company's products include saliva DNA isolation kit, genomic kit and immunoassay products, among others. Its saliva DNA isol …
  • Village Roadshow Ltd：企業の戦略・SWOT・財務情報
    Village Roadshow Ltd - Strategy, SWOT and Corporate Finance Report Summary Village Roadshow Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Success Universe Group Limited
    Success Universe Group Limited - Strategy, SWOT and Corporate Finance Report Summary Success Universe Group Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • Reliance Communications Ltd (RCOM)：企業の財務・戦略的SWOT分析
    Reliance Communications Ltd (RCOM) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and w …
  • Renesas Electronics Corp (6723)：企業の財務・戦略的SWOT分析
    Renesas Electronics Corp (6723) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weak …
  • Dollarama Inc：企業の戦略・SWOT・財務情報
    Dollarama Inc - Strategy, SWOT and Corporate Finance Report Summary Dollarama Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆